HOMAGE aims to provide a biomarker approach that will help identify
In available cohorts, we will identify the most promising ‘omics-based biomarker’ profiles for the pre-symptomatic diagnosis and future prediction of heart failure in patients at risk. The predictive value of the biomarkers for other co-morbidities commonly associated with heart failure and ageing will also be investigated. Furthermore, in a prospective trial, we will investigate the potential for targeting preventive therapy at patients with the greatest likelihood of response and the lowest risk of adverse effects.
Our selection of innovative ‘omics-based biomarkers’ is based on knowledge of biological pathways of the disease, which may facilitate identification of ‘Biotargets’ for future therapies.